July 19, 2022 - Several years ago, scientists studying aging at the Harvard Stem Cell Institute used a somewhat Frankensteinian technique known as parabiosis — surgically joining a young mouse and an old mouse so that they share blood — to see what would happen to the heart and skeletal muscle tissue.
Read More →
May 5, 2022 - Dr. Mark Allen, the co-founder and CEO of Elevian, tells us their experience and about selecting their first target: stroke.
Listen Here (interview begins at 34:35) —>
Read MoreSep. 16, 2021- Elevian, an emerging biotech company developing medicines that restore youthful regenerative capacity with the potential to treat and prevent multiple age-related diseases, today announced that it raised $40 million in an oversubscribed Series A round led by Prime Movers Lab. The funding will enable Elevian to submit an investigational new drug application, scale manufacturing and complete Phase 1 clinical trials for its lead indication of stroke recovery.
Read MoreDec. 3, 2020 - It is early days for antiaging drug research, and even proponents acknowledge the field will face setbacks. But a growing understanding of the biological processes of aging is yielding insights into potential new ways of treating patients today—and prompting some entrepreneurs to imagine a future in which medications could be taken by healthy people to forestall a range of aging-related illnesses.
Read MoreNov. 24, 2020 - Elevian, an emerging biotech company developing medicines that restore youthful regenerative capacity with the potential to treat and prevent multiple age-related diseases, today announced the closing of a $15 million equity financing. Proceeds from the equity financing will enable Elevian to advance recombinant GDF11 (rGDF11) toward the clinic to treat stroke and other age-related diseases.
Read MoreJan. 7, 2020 - The 2nd Annual Longevity Therapeutics Summit will be held on January 28-30 in San Francisco, CA. The Summit highlights the latest developments in aging research and therapeutics that target age-related conditions. Elevian CEO, Mark Allen, will chair and present at the pre-conference workshop on January 28.
Read More →
Read MoreJan. 9, 2019 - In order to succeed in this endeavor, the companies will utilize state-of-the-art techniques in AI-enabled drug discovery.
Read MoreJan. 5, 2019 - Elevian develops regenerative medicines, with the potential to treat and prevent many age-related diseases and extend healthy lifespan, targeting a fundamental mechanism of aging: regenerative capacity, our body’s ability to heal itself, which declines with age.
Read More
Rejuvenation of aged progenitor cells by exposure to a young systemic environment.
Conboy IM, Wagers AJ et al. Nature, 2005.
Read MoreSept. 6, 2018 - Elevian, a new company developing medicines that restore youthful regenerative capacity, with the potential to treat and prevent age-related disease, launches at TechCrunch Disrupt's Startup Battlefield.
Read More
Loffredo FS,...,Wagers AJ, Lee RT. Cell, 2013.
Read More
Restoring Systemic GDF11 Levels Reverses Age-Related Dysfunction in Mouse Skeletal Muscle.
Sinha M,...,Lee RT, Wagers AJ. Science, 2014.
Read More
Vascular and Neurogenic Rejuvenation of the Aging Mouse Brain by Young Systemic Factors.
Katsimpardi L,...,Lee RT, Wagers AJ, Rubin LL. Science, 2014.
Read More
Olson KA et al. European Heart Journal, 2015.
Read More
Walker RG,...,Rubin LL, Wagers AJ, Lee RT. Circulation Research, 2016.
Read More
Structural basis for potency differences between GDF8 and GDF11.
Walker RG,...,Wagers AJ, Lee RT et al. BMC Biology, 2017.
Read More
Onodera K et al. Thorax, 2017.
Read More
Lifelong exercise, but not short-term high-intensity interval training, increases GDF11.
Elliott BT et al. Physiological Reports, 2017.
Read More
Ozek C,…, Rubin LL. Scientific Reports, 2018.
Read More